Transitional Metal-Based Noncatalytic Medicine for Tumor Therapy

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Oncology

Background:

• Nanocatalytic medicine is an emerging strategy for cancer therapeutics, enabling tumor suppression via in situ generation of toxic agents.
• This approach avoids conventional, highly toxic, and nonselective chemotherapeutic drugs.
• Recent advancements focus on stimuli-activated cancer therapies like chemodynamic, photodynamic, and sonodynamic therapy.

Purpose of the Study:

• To review transitional metal-based nanocatalytic medicines for cancer therapy.
• To discuss the catalytic mechanisms of iron, manganese, and copper-based nanocatalysts.
• To outline future challenges in the clinical translation of these nanomedicines.

Main Methods:

• Literature review of nanocatalytic medicine strategies.
• Summary of iron, manganese, and copper-based nanocatalyst applications.
• Analysis of catalytic mechanisms in cancer therapy.

Main Results:

• Transitional metal-based nanocatalysts (Fe, Mn, Cu) show significant potential in cancer treatment due to their catalytic activity and selectivity.
• Various nanocatalytic approaches, including chemodynamic, photodynamic, and sonodynamic therapies, are effective.
• Progress has been made in steering catalytic reactions for targeted tumor suppression.

Conclusions:

• Transitional metal-based nanocatalytic medicines represent a promising frontier in cancer therapeutics.
• Understanding catalytic mechanisms is crucial for optimizing treatment efficacy.
• Overcoming design and clinical conversion obstacles is essential for future therapeutic applications.